Skip to search formSkip to main contentSkip to account menu

lodamin

Known as: mPEG-PLA-TNP-470 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Chronic and recurrent uveitis account for approximately 10% of legal blindness in the western world. Autoimmune uveitis is driven… 
2013
2013
Lodamin, the oral formulation of TNP-470, a methionine aminopeptidase 2 (MetAp2) inhibitor, was previously shown to significantly… 
Highly Cited
2011
Highly Cited
2011
2010
2010
Pathological neovascularization is a hallmark of late stage neovascular (wet) age-related macular degeneration (AMD) and the… 
2010
2010
Abstract : Centers on the development of new medical therapies and regenerative medicine approaches for the treatment of injured… 
Highly Cited
2008
Highly Cited
2008
Targeting angiogenesis, the formation of blood vessels, is an important modality for cancer therapy. TNP-470, a fumagillin analog… 
2008
2008
Despite promising early results, cancer therapy aimed at selective destruction of tumor blood vessels faces several hurdles… 
2008
2008
1118 Targeting angiogenesis, the formation of new blood vessels, is becoming an important strategy for cancer therapy. TNP-470… 
2008
2008
  • P. Goymer
  • Nature Reviews. Cancer
  • 2008
  • Corpus ID: 46098883
inhibitor TNP-470 is a potent suppressor of tumour growth and metastasis, but its use is limited because it requires lengthy…